This page shows the latest DLBCL news and features for those working in and with pharma, biotech and healthcare.
MTEM’s pipeline includes a number of oncology-directed assets, such as a first-generation ETB (MT-3724) in phase 2 development for pre-treated diffuse large B-cell lymphoma (DLBCL)
resulted in objective clinical responses in 47% of patients with mantle cell lymphoma (MCL) and 80% of patients with diffuse large B-cell lymphoma (DLBCL). ... In the DLBCL group, four of the five patients who were treated with VLS-101 had objective
drug conjugate Polivy in combination with Rituxan (rituximab) and bendamustine for the treatment of diffuse large B-cell lymphoma (DLBCL). ... The new treatment option is great news for patients and clinicians, considering that the prognosis for relapsed
B-cell lymphoma (DLBCL) and another spanning multiple solid tumour types.
The EU approval clears Polivy for use in combination with chemotherapy drug bendamustine and anti-CD20 rituximab in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible ... Filings for approval in first-line DLBCL
beyond DLBCL, such as follicular lymphoma (FL), marginal zone lymphoma (MZL) and CLL. ... MorphoSys has already filed tafasitamab with the FDA, as a treatment for patients with r/r DLBCL, and expects a decision by mid-2020.
More from news
Approximately 9 fully matching, plus 58 partially matching documents found.
The phase 2 L-MIND study in diffuse large B-cell lymphoma (DLBCL) showed the combination of tafasitamab with Celgene’s Revlimid (lenalidomide) had an overall response rate of 60%, with
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... Celgene and Juno hope to crash the party
pivotal trial for relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). According to Celgene's press release, regulatory approval for JCAR017 in the US is anticipated in 2019 with ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics
its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
Argentina. Unknown. Clinical. DLBCL: Ph III planned in Argentina. NA. Biocad. ... NA. BC: Breast cancer; DLBCL: Diffuse large B-cell lymphoma; FL: Follycular Lymphoma; NA: Not applicable; NSCLC: Non-Small Cell Lung Cancer; RA: Rheumatoid Arthritis; TT:
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Our goal is to identify and embed transformational patient insights as a fundamental part of the drug development process. As...